Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pharmaceuticals

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,428 result(s) found for: Pharmaceuticals. Displaying page 1 of 222.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-001660-31 Sponsor Protocol Number: 2586 Start Date*: 2005-08-05
    Sponsor Name:The Royal Marsden Hospital NHS Foundation Trust
    Full Title: A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids.
    Medical condition: 10-30% of cancer patients have an unsuccessful outcome when given oral morphine because of intolerable side effects. Oxycodone is an alternative opioid which is commonly used as a second line opioi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002189-11 Sponsor Protocol Number: VX15-661-112 Start Date*: 2019-05-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cyst...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000457-39 Sponsor Protocol Number: VX16-770-127 Start Date*: 2019-05-03
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Randomized, Double-blind, Placebo controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects with Cystic Fibrosis Who are 6 Years of Age and Older and Have Either a 3849 + 10KB...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000946-41 Sponsor Protocol Number: VX19-809-124 Start Date*: 2023-10-17
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 ...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000689-40 Sponsor Protocol Number: VX19-661-012 Start Date*: 2020-02-25
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Granule Formulation of Tezacaftor and Ivacaftor Compared to a Fixed-dose Combination Tablet in Healt...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018320-10 Sponsor Protocol Number: AC-066A302 Start Date*: 2010-07-02
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001565-33 Sponsor Protocol Number: RA101495-02.302 Start Date*: 2020-04-24
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000362-34 Sponsor Protocol Number: SAN-0791 Start Date*: 2023-10-12
    Sponsor Name:Lek Pharmaceuticals d.d.
    Full Title: An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in A...
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005636-29 Sponsor Protocol Number: IDX-03YF Start Date*: 2013-05-17
    Sponsor Name:Idenix Pharmaceuticals, Inc.
    Full Title: 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Act...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004037-10 Sponsor Protocol Number: CE01-119 Start Date*: 2014-10-10
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A phase 1, open-label, multi-centre study to determine the PK and safety of a 5-day oral dosing of solithromycin as add-on therapy to antimicrobial agent administered to adolescent with suspected o...
    Medical condition: suspected or confirmed bacterial infection
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001803-57 Sponsor Protocol Number: CLCZ696B2126 Start Date*: 2017-08-14
    Sponsor Name:Novartis Pharmaceuticals Corp
    Full Title: A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet
    Medical condition: Study in healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005036-20 Sponsor Protocol Number: VEK40624 Start Date*: 2014-02-18
    Sponsor Name:Stellaris Pharmaceuticals ApS
    Full Title: Recombinant Factor VIIa: Local treatment of severe postpartum hemorrhage
    Medical condition: Severe postpartum bleeding
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004868 10071867 Postpartum bleeding LLT
    16.1 100000004868 10071897 Third stage postpartum bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002254-23 Sponsor Protocol Number: VX15-809-014 Start Date*: 2019-06-10
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1, Randomized, Open-label Study to Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Lumacaftor in Combination With Ivacaftor in Healt...
    Medical condition: Healthy Adult Subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000584-31 Sponsor Protocol Number: 402-C-120 Start Date*: 2023-07-06
    Sponsor Name:Pacira Pharmaceuticals, Inc.
    Full Title: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Local Administration of EXPAREL for Postsurgical Analgesia in Pediatric Subjects 12 to Less Than 17 Years of Age
    Medical condition: postsurgical pain
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005914-33 Sponsor Protocol Number: VX21-445-125 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) SE (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003523-34 Sponsor Protocol Number: RA101495-01.202 Start Date*: 2017-04-06
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DK (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-000357-20 Sponsor Protocol Number: 000184 Start Date*: 2015-11-19
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients with Prostate Cancer
    Medical condition: FIRMAGON is indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-002276-42 Sponsor Protocol Number: 61/O4/OX/Rh Start Date*: 2004-12-13
    Sponsor Name:IVAX Pharmaceuticals s.r.o.
    Full Title: Tolerability and safety of Oxamet® in patients with acute rhinitis
    Medical condition: Acute rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001523-39 Sponsor Protocol Number: D1050300 Start Date*: 2013-11-08
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001378-13 Sponsor Protocol Number: 001 Start Date*: 2017-02-02
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.
    Medical condition: cervical dystonia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10064124 Cervical dystonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 14:12:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA